# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target fr...
HC Wainwright & Co. analyst Edward White maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price ...
B of A Securities analyst Jason Zemansky maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price targ...
The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at...
Barclays analyst Peter Lawson maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target f...
FDA has approved Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (G...